D
ALX Oncology Holdings Inc. ALXO
$1.55 -$0.04-2.52% NASDAQ
Recommendation
Prev Close
$1.59
Volume
123,047
Avg Vol (90D)
863,132
Market Cap
$85.15M
Dividend & Yield
--
52-Week Range
$0.40 - $2.27
P/E (TTM)
--
EPS (TTM)
-$2.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
10/30/2025 - Globe Newswire
Alx Oncology's ALX2004: A Promising Phase 1 Study Targeting EGFR in Solid Tumors
10/27/2025 - TipRanks Financial Blog
ALX Oncology (NASDAQ:ALXO) Earns "Sell (D-)" Rating from Weiss Ratings
10/25/2025 - MarketBeat
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
10/23/2025 - Globe Newswire
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
10/19/2025 - MarketBeat
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
10/14/2025 - Zacks Investment Research
ALX Oncology (NASDAQ:ALXO) Given "Sell (D-)" Rating at Weiss Ratings
10/8/2025 - MarketBeat
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/3/2025 - Globe Newswire
Goldman Sachs Group Inc. Sells 195,795 Shares of ALX Oncology Holdings Inc. $ALXO
9/29/2025 - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
9/24/2025 - MarketBeat
ALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Purchases 21,070 Shares
9/19/2025 - MarketBeat
ALX Oncology (NASDAQ:ALXO) CEO Jason Lettmann Acquires 71,163 Shares
9/19/2025 - MarketBeat
Video: Friday 9/19 Insider Buying Report: AROC, ALXO
9/19/2025 - Market News Video
Insider Buying: ALX Oncology (NASDAQ:ALXO) CEO Purchases 71,163 Shares of Stock
9/19/2025 - MarketBeat
Insider Buying: Jason Lettmann Acquires 92,233 Shares of ALX Oncology Holdings Inc (ALXO)
9/18/2025 - GuruFocus
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
9/12/2025 - Globe Newswire
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts
9/1/2025 - MarketBeat
Alx Oncology's Earnings Call: Optimism Amidst Challenges
9/1/2025 - TipRanks Financial Blog
ALX Oncology to Participate in Upcoming Investor Conferences in September
8/29/2025 - Globe Newswire
Insider Buys Additional US$58k In ALX Oncology Holdings Stock
8/21/2025 - Simply Wall St
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
8/19/2025 - Globe Newswire
Alx Oncology Faces Nasdaq Delisting Risk Amid Stock Price Slump
8/14/2025 - TipRanks Financial Blog
ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ...
8/13/2025 - GuruFocus
Q2 2025 ALX Oncology Holdings Inc Earnings Call Transcript
8/13/2025 - GuruFocus
ALX Oncology Holdings Inc. 2025 Q2 - Results - Earnings Call Presentation
8/13/2025 - SeekingAlpha
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$117.63M
EBIT (TTM)
-$118.47M
Net Income (TTM)
-$116.57M
Balance Sheet
Total Assets (Q)
$95.32M
Total Debt (Q)
$16.18M
Total Liabilities (Q)
$30.91M
Book Value Per Share (Q)
$1.20
Cash Flow
Cash from Operations (TTM)
-$105.49M
Cash from Investing (TTM)
$108.84M
Cash from Financing (TTM)
$422.00K
Net Change in Cash (TTM)
$3.77M
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.50
7-Day Total Return
-5.49%
30-Day Total Return
42.20%
60-Day Total Return
121.11%
90-Day Total Return
240.58%
Year to Date Total Return
-0.64%
1-Year Total Return
12.32%
2-Year Total Return
-77.47%
3-Year Total Return
-87.23%
5-Year Total Return
-96.08%
52-week Low
Jun 27, 2025 - $0.40
52-week High
Oct 06, 2025 - $2.27
Valuation
Market Cap
$85.15M - Micro Cap
Enterprise Value
$22.01M
Price/Sales (TTM)
--
Price/Book (Q)
1.32
Dividends and Shares
Shares Outstanding
53.45
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.alxoncology.com
Phone Number
650 466 7125
Address
323 Allerton Avenue
South San Francisco, CA 94080
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept... more
NASDAQ 10/30/2025 4:00PM Eastern Quotes delayed